![](/content/dam/global/hcpportal/en_IE/Images/trelegy-mt/hrqol/hero-image-1.png)
Trelegy Ellipta and health-related quality of life (HRQoL)
Single-inhaler Triple Therapy could help your COPD patients breathe better from today1,2
![Image of person out of breath Image of person out of breath](/content/dam/global/hcpportal/en_IE/Images/trelegy-mt/hrqol/icon03.png)
COPD can make activities such as attending social events with friends or playing with their grandchildren more difficult, impacting quality of life3
![Image of person with arms raised Image of person with arms raised](/content/dam/global/hcpportal/en_IE/Images/trelegy-mt/hrqol/hr-icon.png)
TRELEGY Ellipta: Statistically superior improvement vs. budesonide/formoterol in HRQoL1
![Image of person with arms raised Image of person with arms raised](/content/dam/global/hcpportal/en_IE/Images/trelegy-mt/hrqol/hr-icon.png)
TRELEGY Ellipta: Statistically superior improvement vs. a LAMA/LABA (UMEC/VI) in HRQoL2
Statistically superior improvement in HRQoL vs. budesonide/formoterol1
![Graph showing statistically superior improvement in HRQoL vs. budesonide/formoterol Graph showing statistically superior improvement in HRQoL vs. budesonide/formoterol](/content/dam/global/hcpportal/en_IE/Images/trelegy-mt/hrqol/hr-chart02-updated.png)
Adapted from Lipson et al. 20171
HRQoL determined according to the St. George's Respiratory Questionnaire (SGRQ). Find out more lower down this page. SGRQ MCID=4.0 unit change
The figures have been rounded from -6.57 and -4.33, respectively
Data from the FULFIL study comparing TRELEGY Ellipta OD to BUD/FOR.1 Co-primary endpoints of change from baseline in trough FEV1 and SGRQ score at Week 24 were both met
Statistically superior improvement in HRQoL vs. a LAMA/LABA (UMEC/VI)2
![Graph showing statistically superior improvement in HRQoL vs. a LAMA/LABA Graph showing statistically superior improvement in HRQoL vs. a LAMA/LABA](/content/dam/global/hcpportal/en_IE/Images/trelegy-mt/hrqol/hr-chart03.png)
Adapted from Lipson et al. 20182
HRQoL determined according to the St. George's Respiratory Questionnaire (SGRQ). Find out more lower down this page. SGRQ MCID=4.0 unit change
Data from the IMPACT trial comparing TRELEGY Ellipta OD to an ICS/LABA (FF/VI) and a LAMA/LABA (UMEC/VI).2 Co-primary endpoints of annual rate of on-treatment moderate/severe exacerbations for TRELEGY Ellipta vs. both comparators were met. Change from baseline in SGRQ score at Week 52 was a secondary endpoint
Key trial design
Get started with Trelegy Ellipta
Footnotes
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; LABA, long- acting ß2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; MCID, minimal clinically important difference; OD, once daily; UMEC, umeclidinium; VI, vilanterol
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA4
References
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). 2024.
- TRELEGY Ellipta SmPC. Available at www.medicines.ie. Accessed April 2024.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark of the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with
![Innoviva logo Innoviva logo](/content/dam/global/hcpportal/en_IE/trelegy/identifying-patient/innoviva-logo.jpg)
Last Updated: April 2024 PM-IE-FVU-WCNT-240003